Petrovsky National Research Center of Surgery, Moscow 119991, Russia.
Peoples' Friendship University of Russia named after Patrice Lumumba (RUDN University), Moscow 117198, Russia.
Int J Mol Sci. 2023 Jun 18;24(12):10308. doi: 10.3390/ijms241210308.
Cardiovascular diseases (CVD) and, in particular, atherosclerosis, remain the main cause of death in the world today. Unfortunately, in most cases, CVD therapy begins after the onset of clinical symptoms and is aimed at eliminating them. In this regard, early pathogenetic therapy for CVD remains an urgent problem in modern science and healthcare. Cell therapy, aimed at eliminating tissue damage underlying the pathogenesis of some pathologies, including CVD, by replacing it with various cells, is of the greatest interest. Currently, cell therapy is the most actively developed and potentially the most effective treatment strategy for CVD associated with atherosclerosis. However, this type of therapy has some limitations. In this review, we have tried to summarize the main targets of cell therapy for CVD and atherosclerosis in particular based on the analysis using the PubMed and Scopus databases up to May 2023.
心血管疾病（CVD），特别是动脉粥样硬化，仍然是当今世界主要的死亡原因。不幸的是，在大多数情况下，CVD 的治疗是在出现临床症状后开始的，旨在消除这些症状。因此，早期针对 CVD 的发病机制的治疗仍然是现代科学和医疗保健中的一个紧迫问题。细胞疗法旨在通过用各种细胞替代来消除某些疾病（包括 CVD）发病机制中的组织损伤，这是最受关注的。目前，细胞疗法是最活跃的研究领域，也是与动脉粥样硬化相关的 CVD 的最有效治疗策略之一。然而，这种治疗方法存在一些局限性。在这篇综述中，我们试图根据截至 2023 年 5 月使用 PubMed 和 Scopus 数据库的分析，总结基于细胞的 CVD 和动脉粥样硬化治疗的主要靶点。
